MX2022012366A - Metodos para generar neuronas de dopamina del mesencefalo, neuronas del mesencefalo, y usos de las mismas. - Google Patents

Metodos para generar neuronas de dopamina del mesencefalo, neuronas del mesencefalo, y usos de las mismas.

Info

Publication number
MX2022012366A
MX2022012366A MX2022012366A MX2022012366A MX2022012366A MX 2022012366 A MX2022012366 A MX 2022012366A MX 2022012366 A MX2022012366 A MX 2022012366A MX 2022012366 A MX2022012366 A MX 2022012366A MX 2022012366 A MX2022012366 A MX 2022012366A
Authority
MX
Mexico
Prior art keywords
midbrain
neurons
methods
generating
dopamine neurons
Prior art date
Application number
MX2022012366A
Other languages
English (en)
Spanish (es)
Inventor
Lorenz Studer
Tae- Wan Kim
So- Yeon KOO
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2022012366A publication Critical patent/MX2022012366A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022012366A 2020-04-02 2021-04-02 Metodos para generar neuronas de dopamina del mesencefalo, neuronas del mesencefalo, y usos de las mismas. MX2022012366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063004138P 2020-04-02 2020-04-02
PCT/US2021/025596 WO2021203009A1 (en) 2020-04-02 2021-04-02 Methods of generating midbrain dopamine neurons, midbrain neurons and uses thereof

Publications (1)

Publication Number Publication Date
MX2022012366A true MX2022012366A (es) 2022-12-15

Family

ID=77929755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012366A MX2022012366A (es) 2020-04-02 2021-04-02 Metodos para generar neuronas de dopamina del mesencefalo, neuronas del mesencefalo, y usos de las mismas.

Country Status (12)

Country Link
US (1) US20230143486A1 (cg-RX-API-DMAC7.html)
EP (1) EP4127137A4 (cg-RX-API-DMAC7.html)
JP (2) JP7877221B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220164012A (cg-RX-API-DMAC7.html)
CN (1) CN115768875A (cg-RX-API-DMAC7.html)
AU (1) AU2021248640A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019881A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177525A1 (cg-RX-API-DMAC7.html)
IL (1) IL296919A (cg-RX-API-DMAC7.html)
MX (1) MX2022012366A (cg-RX-API-DMAC7.html)
WO (1) WO2021203009A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211266B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220639A2 (en) * 2022-05-10 2023-11-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for improved memory in the aging
WO2024259119A2 (en) 2023-06-13 2024-12-19 Aspen Neuroscience, Inc. Methods for differentiating dopaminergic neurons from stem cells
AU2025217196A1 (en) 2024-01-31 2026-07-09 Bluerock Therapeutics Lp Igfbp2 in cell culture
WO2025252180A1 (zh) * 2024-06-05 2025-12-11 中国科学院脑科学与智能技术卓越创新中心 中脑多巴胺能祖细胞群的体外制备方法
WO2026006245A1 (en) * 2024-06-25 2026-01-02 Bluerock Therapeutics Lp Three-dimensional culturing of pluripotent stem cells for improved differentiability
WO2026096366A1 (en) 2024-10-28 2026-05-07 Bluerock Therapeutics Lp Compositions and methods for determination of pluripotent stem cell differentiability
CN121759465B (zh) * 2026-03-05 2026-07-14 上海元戊医学技术有限公司 兼具条件性免疫逃逸功能和自杀功能的神经细胞、其建立方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012332269B2 (en) * 2011-11-04 2018-05-31 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (DA) neurons for engraftment
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
CN105209607B (zh) * 2013-04-05 2020-02-07 大学健康网络 产生软骨细胞谱系细胞和/或类软骨组织的方法和组合物
JP6756610B2 (ja) * 2013-04-26 2020-09-16 メモリアル スローン ケタリング キャンサー センター 多分化能細胞および多能性細胞の分化を方向付けることによって発生させる皮質介在ニューロンおよびその他のニューロン細胞
SG11201807487WA (en) * 2016-03-14 2018-09-27 Agency Science Tech & Res Generation of midbrain-specific organoids from human pluripotent stem cells

Also Published As

Publication number Publication date
WO2021203009A1 (en) 2021-10-07
EP4127137A4 (en) 2024-05-22
KR20220164012A (ko) 2022-12-12
ZA202211266B (en) 2023-05-31
US20230143486A1 (en) 2023-05-11
CA3177525A1 (en) 2021-10-07
EP4127137A1 (en) 2023-02-08
JP7877221B2 (ja) 2026-06-22
CN115768875A (zh) 2023-03-07
JP2025184905A (ja) 2025-12-18
BR112022019881A2 (pt) 2022-11-22
IL296919A (en) 2022-12-01
JP2023520466A (ja) 2023-05-17
AU2021248640A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
CO2022010241A2 (es) Inhibidores de sos1
MX389700B (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
CO2022009438A2 (es) Fluoroalquil-oxadiazoles y sus usos
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
MX2022002532A (es) Métodos para generar y aislar neuronas de dopamina del mesencéfalo.
UY37349A (es) Composiciones y métodos para inhibir masp-3 para el tratamiento de varias enfermedades y trastornos
CL2020000911A1 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
MX380866B (es) Composiciones y métodos para modular la expresión del factor b del complemento.
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
UY36091A (es) Compuesto heterocíclico que contiene nitrógeno
GT201700099A (es) 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
MX2019001036A (es) Tratamiento y prevencion de los trastornos del sueño.
DOP2020000072A (es) Amidas de imidazopiridina sustituidas y su uso
EA201790626A1 (ru) Макроциклические ингибиторы lrrk2-киназы
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
CL2023000371A1 (es) Composiciones y métodos para inhibir la expresión de plp1.
MX2021000363A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.
MX2017002388A (es) Composiciones para fibras de queratina.